. Overview Connect Biopharma, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target interleukin-4-receptor alpha (IL-4R). Significant Unmet Need and Market Opportunity in Asthma Asthma is a chronic inflammatory disease that affects the airways in the lungs and mak...
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001835268-26-000013 | EDGAR | 117K words |
| 2025-03-31 | 2024-12-31 | 0001835268-25-000014 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001835268-25-000058 | EDGAR | 15K words |
| 2025-08-13 | 2025-06-30 | 0001835268-25-000052 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001835268-25-000035 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001835268-26-000012 | EDGAR | 3K words |
| 2026-03-30 | 0001835268-26-000006 | EDGAR | — |
| 2025-12-23 | 0001835268-25-000061 | EDGAR | — |
| 2025-11-12 | 0001835268-25-000057 | EDGAR | — |
| 2025-09-16 | 0001835268-25-000056 | EDGAR | — |
| 2025-08-13 | 0001835268-25-000051 | EDGAR | — |
| 2025-07-22 | 0001835268-25-000047 | EDGAR | — |
| 2025-07-21 | 0001835268-25-000044 | EDGAR | — |
| 2025-07-17 | 0001835268-25-000039 | EDGAR | — |
| 2025-07-09 | 0001628280-25-034551 | EDGAR | — |
72 total filings indexed. 57 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001835268 |
| Ticker | CNTB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | E9 |
| Website | https://www.connectbiopharm.com |
| Listed | 2025-09-03 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report